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A B S T R A C T
Melanoma is an aggressive malignancy originating from pigment-producing melanocytes. The development of targeted therapies (MAPK pathway inhibitors) and
immunotherapies (immune checkpoint inhibitors) led to a substantial improvement in overall survival of patients. However, the long-term eﬃcacy of such treatments
is limited by side eﬀects, lack of clinical eﬀects and the rapidly emerging resistance to treatment. A number of molecular mechanisms underlying this resistant
phenotype have already been elucidated.
In this review, we summarise currently available treatment options for metastatic melanoma and the known resistance mechanisms to targeted therapies. A focus
will be placed on “phenotype switching” as a mechanism and driver of drug resistance, together with an overview of novel approaches to circumvent resistance. A
large body of recent data and literature suggests that tumour progression and phenotype switching could be better controlled and development of resistance
prevented or at least delayed, by combining drugs targeting fast- and slow-proliferating cells.
1. Introduction
Melanoma is a malignancy that develops from melanocytes, the
melanin-producing cells [1]. Despite being a rare type of skin cancer, it
is responsible for the vast majority of skin cancer-related deaths [2].
Additionally, metastatic melanoma is one of the most highly mutated,
heterogeneous and lethal types of cancer [3]. The most prominent
mutations in melanoma aﬀect the serine/threonine kinase BRAF (50%),
the small GTPase NRAS (25%), or the tumour suppressor and negative
regulator of RAS, neuroﬁbromin 1 (NF1) (14%), which all lead to an
increased proliferation and survival [3]. Until recently, the treatment
options for advanced stage melanoma patients were limited to con-
ventional chemotherapeutic drugs with an overall low eﬃcacy and
limited response rate (RR) [4]. Only in the past few years, the pro-
gression-free (PFS) and overall survival (OS) of melanoma patients has
markedly improved by the introduction of targeted and im-
munotherapies [5]. Despite the substantial progress that has been made
in the clinical management of advanced melanoma, treatment failures,
severe side eﬀects and intrinsic as well as acquired resistances against
all forms of current therapies warrant continued research eﬀorts to ﬁnd
more eﬃcient, durable and potentially personalised treatment options.
The identiﬁcation of mechanisms underlying the switch from a drug
sensitive to a drug resistant phenotype has been the focus of melanoma
research in the past few years. This review provides an overview of past
and present treatments and summarises mechanisms of resistance to
targeted therapies and highlights new potential drug targets that have
emerged in recent studies on metabolic eﬀects, slow cycling tumour
cells, phenotypic switching, as well as ER-stress, autophagy and
miRNA-mediated resistance mechanisms.
2. Therapeutic options for melanoma patients
Current therapeutic options for melanoma patients mainly consist of
surgical excision, chemotherapy, immunotherapy, and targeted therapy
[6]. These therapies can be administered as single agents or in combi-
nation depending on the stage of the disease, location and genetic
proﬁle of the tumour, as well as the general health and the age of the
patient (Fig. 1).
The main curative treatment for accessible and early stage cuta-
neous melanoma tumours is surgery. Metastatic melanoma, however,
is very unlikely to be cured by surgery due to the often high number of
metastases, low accessibility and the diﬃcult detection of small meta-
static lesions by commonly used imaging tools [7]. Chemotherapy,
consisting of temozolomide (TMZ) and dacarbazine (DTIC), is com-
monly used in late stage melanoma patients with progressive, re-
fractory, or relapsed disease [8] (Fig. 1). In addition, high doses of
interferon α-2b (IFNα-2b) and interleukin-2 (IL-2), which have been
FDA-approved as single agents in 2011 and 1998, respectively, are
applied to resected stage II/III patients, and in some cases to stage IV
melanoma patients albeit with limited success [9,10]. A major progress
in treatment of several solid cancers was made by monoclonal anti-
bodies that function as immune checkpoint inhibitors [11–13]
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(Fig. 1). The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
inhibitor (ipilimumab) and programmed cell death protein 1 (PD-1)
inhibitors (pembrolizumab and nivolumab) show an increased overall
response rate (RR), median PFS and OS in melanoma patients. Albeit
the convincing results in about 30% of advanced stage patients, most
patients either do not respond to immunotherapies or have severe side
eﬀects, which make a cessation of treatment necessary [14]. Oncolytic
viruses have recently been integrated in anti-tumour therapies due to
their capacity of directly lysing tumour cells, leading to the release of
soluble antigens and interferons that drive antitumor immunity [15].
Currently, the attenuated herpes simplex virus-based oncolytic virus
talimogene laherparepvec (T-VEC) is the only approved oncolytic virus
for cancer treatment and has been FDA-approved in 2015 as local
treatment of unresectable advanced stage melanoma [5,15] (Fig. 1).
Although the use of oncolytic viruses in combination with targeted
therapies or immunotherapies has shown promising results, only lim-
ited data on optimal dosing and scheduling of the diﬀerent therapies
exists, and an appropriate patient eligibility for T-VEC-based mono- or
combination therapy is still lacking [16].
The identiﬁcation of mutations in the serine/threonine kinase
BRAF, which result in the constitutive activation of the MAPK pathway
in>50% of melanoma patients, has fuelled the generation of targeted
therapies with small molecule inhibitors acting on mutated BRAF [17]
(Fig. 1). Vemurafenib was the ﬁrst FDA approved BRAF inhibitor
(BRAFi) to be administered in patients with advanced stage melanoma
from 2011 onwards, as it showed improved PFS and OS and signiﬁcant
tumour reduction compared to chemotherapy [18]. Two years later,
another BRAF-speciﬁc inhibitor, dabrafenib was FDA-approved, which
had fewer side eﬀects and higher potency than vemurafenib [4,19].
Although these inhibitors initially showed an excellent response with
signiﬁcant reduction of tumour burden, long-term success is still scarce
because of the development of drug resistance, which will be further
discussed below [20].
Due to the frequent BRAFi-induced reactivation of the MAPK
pathway, MEK inhibitors (MEKi) have been developed (Fig. 1). Tra-
metinib, which blocks MEK1/2, was the ﬁrst MEKi for metastatic
melanoma to receive FDA approval in 2013 [21]. The combined ad-
ministration of BRAFi and MEKi (Dabrafenib/Trametinib or Vemur-
afenib/Cobimetinib) extends the PFS compared to BRAFi monotherapy
[22,23]. However, once again and similar to BRAFi monotherapy, pa-
tients also become irresponsive to the combined treatment within sev-
eral months of treatment [20,24]. The most recent FDA-approved tar-
geted therapy for advanced stage un-resectable melanoma is the
combination of Encorafenib (BRAFi)/Binimetinib (MEKi), that appears
to eﬃciently delay resistance. BRAF-mutant patients showed a further
improvement in PFS and OS compared to Vemurafenib monotherapy
[25]. Moreover, recent clinical data show promising results in stage III
melanoma patients treated with adjuvant immune- or targeted thera-
pies. For instance, adjuvant pembrolizumab as well as adjuvant dab-
rafenib/trametinib combination therapy led to a signiﬁcantly lower risk
of recurrence in stage III BRAFmutant melanoma patients [26,27].
The beneﬁts of MAPKi and immune checkpoint inhibitor-based
therapies fuelled the interest in combining these two therapeutic regi-
mens to achieve more durable therapy responses in melanoma patients.
Although checkpoint inhibitors have shown promising eﬀects in BRAFi-
resistant tumours [5], treating patients with immunotherapy after tar-
geted therapy and thus after development of resistance is rather in-
eﬃcient, as the tumours appear to be less responsive to immunotherapy
due to the depletion of intra-tumoral T cells, CD8 T cell exhaustion, as
well as lack of antigen presentation [28,29]. Consequently, the beneﬁts
of starting patient treatment with targeted therapy followed by im-
munotherapy or vice versa, as well as the emerging irresponsiveness,
remain to be determined and are currently being investigated in on-
going clinical trials [5].
3. Mechanisms of resistance to targeted therapy
3.1. Re-activation of the MAPK pathway
Although BRAFi and MEKi eﬃciently inhibit the MAPK pathway by
reducing ERK activation and thus stalling cell proliferation in cells
harbouring mutated BRAF, MAPK pathway reactivation occurs in up to
80% of BRAFi-resistant tumours, indicating that tumour cells highly
depend on the MAPK pathway and rapidly adapt to its inhibition [30].
The main mechanisms leading to MAPK reactivation and sustained ERK
signalling involve alterations in BRAF, NRAS, MEK, and neuroﬁbromin
1 (NF1) [31,32] (Fig. 2). Additionally, the expression of the RAF iso-
form, CRAF (RAF1), can reduce the sensitivity to BRAFi and drive re-
sistance via direct MEK activation or via paradoxical transactivation of
RAF dimers and subsequent ERK signalling [33]. Also, the kinase COT,
also known as TPL2 or MAP3K8, which directly activates MEK/ERK
signalling in a RAF-independent manner, is often elevated in BRAFi-
resistant tumours [34]. As BRAF depletion leads to an increase in COT
protein levels, it was suggested that BRAF might antagonize COT ex-
pression levels by altering COT protein stability [35]. Subsequently,
COT expression is suﬃcient to re-activate MAPK signalling by directly
Fig. 1. Approved treatment options for pa-
tients with unresectable metastatic mela-
noma. The ﬁrst-line treatment for melanoma
patients highly depends on the BRAF muta-
tion status as well as how quickly the disease
progresses. BRAF-mutant melanoma patients
can receive targeted therapies or im-
munotherapies as ﬁrst-line treatment. As
treatment responses to single-agent im-
munotherapy may take longer, targeted
therapies with BRAFi monotherapy or in
combination with MEKi are preferred if an
early response is needed in BRAF-mutant
patients. On the other hand, melanoma pa-
tients with BRAF wild type tumours usually
receive immunotherapies as ﬁrst-line treat-
ment. Patients that do not respond to BRAFi
as ﬁrst-line treatment can receive im-
munotherapies as second line treatment, and
vice-versa. Additionally, non-targeted thera-
pies can be administered as second line
treatment using chemotherapeutic agents such as dacarbazine or temozolomide. Additionally, melanoma tumours can be treated locally using oncolytic virus-based
therapy (T-VEC).
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activating MEK and is most likely responsible for the de-novo resistance
to BRAFi in ~10% of BRAFmutant melanomas [35]. Furthermore, BRAF
allele ampliﬁcation or splice variants, present in up to 30% of patients
with BRAFi resistant tumours, were shown to lead to enhanced RAF
dimerisation and MEK association due to increased BRAF S729 phos-
phorylation [36]. In order to reduce the paradoxical BRAFi-induced
ERK activation, a new generation of so-called paradox-breaking BRAFi
is currently being tested [37].
3.2. Activation of substitutive pathways
Apart from MAPK signalling, the PI3K-mTOR pathway is most
commonly activated in drug resistant melanomas (Fig. 2). Increased
PI3K signalling can be due to loss of function via gene mutation or
deletion of PTEN in 10% of melanomas, or the activation of receptor
tyrosine kinases (RTKs) [38–41]. Remarkably, the increased RTK levels
can also originate from reduced proteolytic shedding of cell surface
receptors in MAPKi-treated cells [42]. The reduced levels of circulating
RTKs can result in an accumulation of RTKs on the cell surface, which
increases the ﬂux through proliferation and survival pathways, al-
lowing the cell to bypass the inhibition of ERK signalling [42].
3.3. Tumour microenvironment
The tumour microenvironment is another important factor in drug
resistance, as stromal cells have been shown to promote intrinsic re-
sistance to BRAFi through secretion of growth factors and subsequently
activating the MAPK or PI3K pathways [43–45] (Fig. 2). Besides, mel-
anoma progression has been linked to an increased abundance of the
extracellular matrix (ECM) proteins such as collagen, which can confer
stiﬀer and more rigid properties to the ECM that favour tumour cell
proliferation [46]. The overall density of melanocytes throughout life
appears to be controlled, among others, by the Hippo signalling
pathway, which plays a role in controlling organ size in animals by
negatively regulating YAP (Yes-associated protein) and TAZ (tran-
scriptional coactivator with PDZ-binding motif) activity [47,48].
Fig. 2. Common mechanisms of resistance to targeted therapies. Reactivation of the MAPK pathway (80% of resistance cases) and alternative pathways most
commonly occurs via mechanisms involving activating mutations in genes involved in proliferation and survival, RAF-mediated resistance mechanisms, loss of
tumour suppressor genes, as well as the tumour microenvironment.
I. Kozar, et al. %%$5HYLHZVRQ&DQFHU²

Interestingly, collagen stiﬀness appears to be regulated by ﬁbroblast-
secreted TGF-β, which in turn regulates nuclear YAP localisation as well
as melanoma cell adhesion [46,49]. Consequently, YAP/TAZ and their
transcriptional binding partner TEAD (TEF transcription factors/TEA
domain) are connected to the de-diﬀerentiated and invasive phenotype
and have further been shown to initiate tumour progression and me-
tastasis, as well as confering drug resistance to targeted therapies in
melanoma [50–52]. The involvement of this important signalling
pathway in evading targeted therapies will be discussed in more detail
in the section on “phenotype switching”.
3.4. Autophagy and ER stress
Tumour cells can adapt to drug-induced stress by upregulating au-
tophagy, which was increased in 74% of patients treated either with
BRAFi monotherapy or in combination with a MEKi, resulting in lower
RR and PFS [53–55]. The mechanisms leading to a BRAFi-mediated
autophagy induction include ER stress and TAM (TYRO3, AXL, MER)
receptor pathway activation [56–58]. Thus, the application of the au-
tophagy inhibitor hydrochloroquine (HCQ) was able to re-sensitize re-
sistant cells to BRAFi [53,59]. Furthermore, an excessive increase in ER
stress-mediated autophagy can lead to cancer cell death [60]. HA15, a
thiazole benzenesulfonamide-based compound that speciﬁcally targets
the chaperone BiP/GRP78/HSPA5 caused increased ER stress and
subsequently apoptosis and autophagy, which was shown to trigger cell
death of both BRAFi-sensitive and -resistant cells [60]. Compounds
triggering autophagy and/or apoptosis alone or in combination with
targeted therapies might therefore constitue a promising group of new
treatment approaches.
3.5. miRNA-mediated resistance mechanisms
MicroRNAs (miRNAs) are ~22 nucleotide short non-coding RNA
molecules known to regulate the expression of genes and proteins in-
volved in the MAPK as well as other resistance-associated pathways
[61,62]. In this context, miR-509-3p, miR-204-5p, and miR-211-5p are
rapidly upregulated in response to short-term BRAFi treatment [63,64].
miR-204-5p and miR-211-5p whose expression is induced by the tran-
scription factors signal transducer and activator of transcription 3
(STAT3) and Microphthalmia-associated transcription factor (MITF),
respectively, appear to confer BRAFi resistance by reactivating the
MAPK or PI3K/AKT pathway, while the exact eﬀect of drug-induced
and resistance-associated miR-509-3p upregulation remains to be elu-
cidated [63–65]. Additionally, miR-550a-3-5p, which acts as a tumour
suppressor in several diﬀerent cancers, is downregulated in resistant
melanomas, and it has the potential to reverse BRAF-mediated re-
sistance by directly targeting YAP, which can mediate drug resistance
[50]. A more exhaustive list of miRNAs involved in drug resistance can
be found elsewhere [65,66].
3.6. Therapy-mediated selection of resistant tumour cell subpopulations
Intra-tumour heterogeneity, which mostly results from genetic and
epigenetic variations, is considered to impact on disease evolution and
progression [67]. Consequently, drug resistance can arise by a “Dar-
winian-type” selection of pre-existing subclones with cancer stem cell-
like properties that are able to withstand drug treatment [68]. Alter-
natively, cancer cells can become resistant by acquiring genetic muta-
tions or by rewiring the epigenome or metabolome under drug treat-
ment-mediated selection pressure, in a “Lamarckian-type process”
[69,70]. It is unclear whether the observed adaptations of cancer cells
arise from selection of pre-existing subclones or rather by tumour cell
plasticity or both. Schaﬀer et al. have observed that cells do not accu-
mulate mutations that would provide a selective advantage in presence
of the BRAFi, but rather that cells develop resistance to BRAFi by
temporary and reversible adaptations to selective pressure (cell
plasticity), a concept that is also supported by previous studies [28,68].
High levels of i.e. AXL, EGFR, and WNT5A have been associated with
the resistant phenotype in melanoma and could be a potential me-
chanism of resistance [68]. These genes are expressed sporadically on
single cell level prior to drug exposure, thus the cells that are capable of
temporarily upregulating these genes in presence of BRAFi are more
likely to become resistant [68,71,72]. The transient transcriptional
state is converted to a stably resistant state upon drug-induced epige-
netic reprogramming, which is initiated by the SOX10-mediated de-
diﬀerentiation, and thereby activating several transcription factors,
including TEAD [68]. SOX10 is known to regulate neural crest devel-
opment in melanocytes [73], whereas TEADs play a role in regulating
invasion in melanoma [74]. These data suggest that the transition to the
stably resistant state is characterised by a generalised de-diﬀerentiation
followed by activation of several diﬀerent new signalling pathways,
which confer survival advantages in the presence of drugs.
4. Phenotype switching
Melanoma cells are not only capable of rapidly adapting to therapies
by acquiring mutations, but they also tend to switch their molecular
and cellular phenotype in an epithelial-to-mesenchymal transition
(EMT)- like manner, in order to bypass drug treatment. The most
common phenotypic changes that melanoma cells undergo to escape
inhibition are linked to the expression of the master transcription factor
MITF and the RTK AXL and implicate, among others, diﬀerentiation/de-
diﬀerentiation, changes in proliferation rates, and metabolic rewiring
(Fig. 3). MITF is a melanocyte lineage-speciﬁc transcription factor that
is required for melanoblast survival, it plays important roles in mela-
nocyte development from neural crest precursors, and it regulates the
expression of pigment-producing enzymes and proteins participating in
melanosome export in response to environmental triggers (e.g. UV) and
extracellular signals (e.g. melanocyte stimulating hormone, MSH) [75].
AXL, on the other hand, belongs to the TAM (TYRO3, AXL, MERTK)
family of RTKs, which are commonly expressed on macrophages and
which are activated in response to the Growth arrest-speciﬁc 6 (GAS6),
thus playing a role in inﬂammatory responses [57]. Several recent
studies have attributed an important role to AXL in melanoma, as its
level are often elevated and inversely correlate with MITF expression
Fig. 3. MITF-linked phenotype switching. Proliferation rate based on the mo-
lecular phenotype and MITF levels (diﬀerentiation). Melanoma tumours are
highly heterogeneous with subpopulations of cells expressing high or low MITF
levels, whichs usually respond well to targeted therapies. However, during drug
treatment, tumours can switch their phenotype to an MITFhigh or AXLhigh slow
proliferating state in order to bypass BRAFi.
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patterns in BRAFi-resistant melanomas [71,72,76,77]. In the following
paragraphs, we provide an overview of most important phenotypic
switches in melanoma that are often associated with MITF and AXL
expression patterns.
4.1. Diﬀerentiation/De-diﬀerentiation
The invasive and de-diﬀerentiated phenotype is a prerequisite of
cancer metastasis. It has been demonstrated that melanoma cells have a
de-diﬀerentiated phenotype during the process of invasion and metas-
tasis formation, which is characterised by low pigmentation and re-
duced proliferation. Once the cells reach the secondary site where the
metastatic growth is formed, cells switch back to a diﬀerentiated,
highly pigmented and proliferative phenotype [78]. These observations
indicate that the switch to a diﬀerentiated phenotype is most probably
induced by factors from the microenvironment (e.g. endothelin 3
(EDN3)) [79]. MITF expression heterogeneity is a commonly observed
phenomenon with high and low MITF expressing subpopulations of
cells, which have been suggested to confer diﬀerent phenotypes, as well
as modulate sensitivity to drug treatment [80,81] (Fig. 3). Recently,
Tsoi and colleagues have identiﬁed four distinct diﬀerentiation states in
melanoma thus providing evidence for the development of drug re-
sistance through a stepwise de-diﬀerentiation process with inter-
mediate transcriptional programs, further highlighting the plasticity of
melanoma cells. The four phenotypes (undiﬀerentiated, neural crest
like, transitory, melanocytic) have overlapping characteristics and can
be deﬁned by the expression of a deﬁned set of genes (e.g. MITF, AXL)
[80]. Subsequently, melanoma cells can bypass targeted therapies by
transitioning from one phenotype to another, accompanied by diﬀer-
ential MITF expression. While the role of MITF in diﬀerentiation is well
described, more and more studies link MITF expression levels to the cell
proliferation rate.
4.2. Proliferation rate
Current cancer therapies mainly target fast proliferating cells,
leaving slow-proliferating cells largely undamaged. Consequently, these
slowly proliferating cells often become enriched during treatment and
gain proliferative characteristics, causing tumour relapse [82] (Fig. 3).
The switch to a slow proliferating phenotype is often mediated via
histone demethylase-mediated chromatin remodelling factors, such as
Jumonji/ARID domain-containing protein 1B (JARID1B) that can be
regulated by hypoxia and several cytokines, and which lead to an in-
creased ﬂux through the PI3K/AKT pathway [83,84]. Although a recent
study has reported that inducible MITF downregulation reﬂects, rather
than causes EMT-like changes, and that low MITF levels result in de-
diﬀerentiation but not necessarily in reduced proliferation or pheno-
type switching [85], several other studies have linked MITF levels to
phenotype switching [71,72] (Fig. 3). These slow cycling melanoma
cells tend to be de-diﬀerentiated and treatment-resistant, which is
characterised by a MITFlow/JARID1Bhigh gene expression proﬁle [84].
Additionally, MITF levels show inverse correlation with other markers
of the slow cycling, invasive and drug-resistant phenotype, such as AXL
or NF-kB [86]. In this context, combinatorial targeting of fast and slow
cycling melanoma cells using a combination of MAPKi and an AXL
antibody-drug conjugate (AXL-107-MMAE) has shown promising re-
sults [76]. Taken together, as slow-cycling cells display invasive prop-
erties and play a role in drug resistance as well as in early tumour re-
lapse in early stage melanoma patients, their enrichment during
treatment could be prevented by combining therapies that target both
fast and slowly proliferating cells [76,82] (Fig. 3).
4.3. Metabolic rewiring
MITF and JARID1B, do not only have an impact on the cell pro-
liferation rate, but together with PPARG coactivator 1 alpha (PGC1α),
they are important mediators of metabolic switches in response to drug
resistance (Fig. 3). While de-diﬀerentiated, slow-cycling and drug-re-
sistant melanoma cells often display a MITFlow/JARID1Bhigh ratio, dif-
ferentiated, slow cycling and therapy-resistant melanoma cells often
have a MITFhigh/PGC1αhigh ratio [87,88]. Also, upon BRAFi treatment,
oxidative phosphorylation (OXPHOS) and reactive oxygen species
(ROS) are increased in a PGC1α-mediated manner, which is directly
triggered by MITF [89]. Usually, cells with high OXPHOS also have
high amounts of ROS, thus slow cycling cells are more sensitive to drugs
that promote oxidative stress [90]. Hence, a combination of BRAFi with
drugs promoting oxidative stress might combat resistance in these slow-
cycling cells. In contrast, reduced OXPHOS levels were observed as an
immediate response to BRAFi, leading to the phosphorylation of the
pyruvate dehydrogenase (PDH) complex as well as to upregulation of
ROS in BRAFV600E and BRAFwt/NRASmutant cells [91]. This BRAFi-in-
duced increase in ROS production could be impaired when using ROS
scavenger compounds [91]. As PDH is only phosphorylated upon short-
term BRAFi and not in BRAFi-resistant melanoma cells, adaptive me-
tabolic rewiring might occur during prolonged drug treatment. Also,
BRAFi-resistant cells with high ROS levels have acquired vulnerability
towards histone deacetylase inhibitors (HDACi), which are known to
further increase ROS levels [92]. Therefore, a sequential treatment with
BRAFi that induce increased ROS, followed by HDACi (Vorinostat),
which further increase ROS levels, might more eﬃciently induce cell
death and eradication of resistant melanoma cells [92].
4.4. Roles of MITF and AXL in phenotype switching
Single cell sequencing has revealed that melanoma tumours display
high intra-tumour heterogeneity and contain both MITFhigh and
MITFlow cells [71,72]. The switch from a MITFhigh/AXLlow to MITFlow/
AXLhigh has been described as a mechanism of resistance to targeted
therapy in a subset of melanoma patients as well as in in vitro cell
culture systems [86,93].
In order to explain the heterogeneous eﬀects of MITF, the so-called
rheostat model was introduced, which among others, describes the
diﬀerent MITF-driven phenotypes [94] (Fig. 3). Subsequently, some
studies reported that a MITFhigh state is associated with MAPKi therapy
resistance and poor prognosis [95,96], whereas others show that a
MITFlow state in combination with high expression levels of several
RTKs (e.g. AXL) is responsible for therapy resistance [76,93]. MITFhigh
tumours were shown to be responsive to MAPKi, however, tumours that
were initially MITFlow upregulate MITF upon treatment, causing the
development of resistance [96].
The paired-box transcription factor (PAX3)-mediated over-
expression of MITF is implicated in reversible early drug resistance [96]
(Fig. 4). Very recently, the same group showed that BRAF regulates
MITF levels via the transcription factors PAX3 and BRN2, providing an
explanation for the dynamic MITF levels in patients in response to
targeted therapy [97]. Targeting the MITF “build-up” via PAX3 deple-
tion could postpone the development of resistance, and re-sensitize
melanoma cells to MAPKi, which inhibit PAX3 via SMAD2/4 and the
salt-inducible kinase (SKI) [96]. SMAD2/4 phosphorylation is induced
by TGF-β, and leads to the formation of SMAD2/4/SKI repressor com-
plex, which supresses the expression of PAX3 and thus the expression of
MITF [96]. On the other hand, drug-resistant melanoma cells and pa-
tient biopsies are rather characterised by a MITFlow, AXLhigh, and
NFκBhigh phenotype [86]. Short-term overexpression of mutant BRAF in
melanocytes induced an MITFlow/NFκBhigh/AXLhigh phenotype, which
was partially reversed using an IκBα super-repressor, suggesting that
AXL is induced by NF-κB signalling [86]. Overexpressing MITF inter-
feres with the BRAF and MEK mutation-induced AXL expression and
TNFα-mediated NFκB induction led to reduced MITF expression and
activity, further supporting the role of MITF and AXL in phenotype
switching [86].
BRAFi resistance can also be mediated via the AXL/AKT axis in
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PTENWT melanoma cells or via ERK signalling in PTENmutant melanoma
cells [38]. MAPK signalling appears to be reactivated in all BRAFi re-
sistant cell lines regardless of PTEN status, whereas AKT signalling is
only reactivated in PTENWT cells. Additionally, the resistant melanoma
cell models with PTENWT exhibited signiﬁcantly higher AXL-driven
AKT activity compared to their corresponding parental cells. On the
other hand, resistant melanoma cell lines with PTEN deﬁciency showed
low AKT activity, which suggests that AKT-mediated BRAFi resistance
is only occurring in melanoma cells with PTENWT [38].
Although, the exact mechanism of how cells switch from one phe-
notype to the other is not yet fully understood, a low MITF/AXL ratio
predicts early resistance to several targeted therapies. In this context,
targeting AXLhigh subpopulations of cells using an AXL antibody drug
conjugate (AXL-107-MMAE) might be beneﬁcial for MITF-low, BRAF-
and NRAS-mutant tumours and a combination of MAPKi and AXLi
could support the elimination of resistant melanoma cells [76]. Al-
though it is generally accepted that either way of the inverse correlation
of MITF and AXL expression levels is an important denominator of cell
plasticity, recent studies in melanoma and other cancers also suggest
YAP-mediated mechanisms to drive switching from one phenotype to
another.
4.5. YAP-mediated phenotype switch
Hippo signalling is often reduced in cancer, leading to an accumu-
lation of YAP/TAZ complexes in the nucleus and augmented cell pro-
liferation and survival via increased ERK1/2 activity [51,79]. YAP-
mediated BRAFi resistance mechanisms have been reported in mela-
noma as the overexpression of YAP can restore BRAFi-mediated ERK
inhibition in drug-sensitive melanoma cell lines [51] (Fig. 4). YAP-in-
duced BRAFi-resistance is mediated via the YAP/TAZ/TEAD axis, fa-
voring an invasive, de-diﬀerentiated and slow cycling phenotype
[46,51]. Verteporﬁn is a drug that blocks YAP function in BRAFi-re-
sistant melanoma cancer stem cells by inhibiting the interaction be-
tween YAP and TEAD, and thereby reducing nuclear YAP/TAZ levels,
ERK1/2 signalling and ﬁnally tumour growth [51,98]. Combination of
BRAF and YAP inhibition could be another promising approach to
overcome drug resistance mechanisms in melanoma (Fig. 4,Fig. 5).
Additionally, ﬁbroblast-secreted TGF-β can induce a switch from a
YAP/PAX3/MITF to a YAP/SMAD/TEAD signalling cascade, which is
supported by the fact that TGF-β can inhibit PAX3, hence reduce the
binding of YAP to the MITF promoter and favoring a MITFlow-TEAD-
regulated invasive phenotype [46,74,99,100] (Fig. 4). While YAP
binding to the MITF promoter decreases in presence of TGF-β, it in-
creases at the promoters of the TEAD target genes, connective tissue
growth factor (CTGF), Cysteine rich protein 61 (CYR61), and AXL, also
establishing a diﬀerentiated slow cycling phenotype [46,101]. A study
in hepatocellular carcinoma (HCC) cells revealed AXL mediated YAP-
dependent oncogenic functions, e.g. increased anchorage-independent
growth, tumour formation, invasion and migration [101]. The AXL
promoter region contains four putative TEAD-binding sites, 1200 bp
upstream of the AXL transcription start site (TSS), and the binding of
YAP and TEAD to the AXL promoter was conﬁrmed by ChIP and luci-
ferase assays in HCC cells [101]. AXL has also been described to acti-
vate the PI3K/AKT and MAPK/ERK pathways, hence high YAP levels
induce AXL expression that in turn induces ERK1/2 and AKT activity
[101] (Fig. 5).
Moreover, the vasoconstrictor peptide endothelin 1 (EDN1) was
shown to promote colorectal cancer (CRC) growth by activating YAP/
TAZ signalling through the G-protein coupled receptors endothelin re-
ceptor A and B (EDNRA and EDNRB), which have an impact on cell
growth [93,102]. EDNRA activation via EDN1 has been reported to
initiate the expression of TEAD-targets, CTGF and CYR61 [103]. Ad-
ditionally, endothelial cells can promote pigmentation through EDNRB
activation [104], and EDN1 has been demonstrated to induce melano-
genesis by activating MITF [105]. Interestingly, the expression of EDN1
maintains MITFhigh as well as AXLhigh cell populations through EDNRB
and EDNRA respectively, and thereby regulates phenotype hetero-
geneity in melanoma [93] (Fig. 4).
Taken together, phenotype switching is of critical importance in
emergence of resistance to BRAFi. Despite the high heterogeneity in
resistance mechanisms, current data obtained from studies on mela-
noma and other cancers suggest that YAP signalling mediates the switch
from one phenotype to another. Several groups have linked MITF and
AXL to diﬀerent molecular phenotypes [71,72], however, the regula-
tion of these distinct phenotypes has been poorly understood. Recent
studies in melanoma have linked EDN1 signalling to MITF and AXL
expression levels [93], as well as tumour microenvironment-mediated
YAP/PAX3 and YAP/TEAD signalling to the MITFhigh and MITFlow
phenotypes, respectively [46]. Studies performed in other cancers (e.g.
HCC and CRC), highly suggest a link between EDN1, AXL, and YAP
signalling, which could also be an important regulatory network in
melanoma worth exploring further (Fig. 4). Fig. 5 summarises the key
molecular pathways that are involved in melanoma drug resistance
mediated by phenotype switching and other mechanisms covered in
this review (Fig. 5).
Fig. 4. Potential mechanisms regulating the MITF/AXL ratio and phenotype
switching. A low MITF/AXL ratio has been linked to BRAFi-resistance in mel-
anoma, however, the exact mechanisms leading to a switch from a diﬀer-
entiated, proliferative, MITFhigh/AXLlow to a de-diﬀerentiated, invasive,
MITFlow/AXLhigh phenotype are not fully understood. The scheme summarises
promising recent data obtained in studies on melanoma and other cancers (e.g.
HCC and CRC) that give insight into the potential regulation of this phenotype
switch including the role of the tumour microenvironment (e.g. collagen stiﬀ-
ness), YAP and EDN signalling.
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5. Conclusion
Melanoma is the posterchild of modern cancer treatment eﬀorts.
The development of BRAFi and MEKi as targeted treatment options for
patients with BRAF-mutant tumours as well as the introduction of im-
mune checkpoint inhibitors contributed profoundly to an increased
overall survival of patients with metastatic melanoma. Nevertheless,
development of resistance to treatment in most patients remains a
major clinical issue. To this date, a myriad of resistance mechanisms to
targeted therapies have been described, ranging from acquired acti-
vating mutations to adaptive processes of cell plasticity in response to
treatment-induced pressure. Interestingly, the dynamic phenotype
switches involving various fundamental cellular processes (cell pro-
liferation rate, diﬀerentiation, and metabolic rewiring) allow mela-
noma cells to robustly resist current therapies. These processes are
generally linked to the master regulator MITF, whose expression levels
inversely correlate with the RTK AXL. Here, we summarised insights
into potential mechanisms regulating phenotype switching. Current
data suggest that targeting de-diﬀerentiated and slowly proliferating
AXLhigh cells in combination with BRAFi could have a signiﬁcant impact
on the overall survival of melanoma patients. Also, the inhibition of the
ECM stiﬀness-induced and YAP-mediated switch between a MITFhigh
and AXLhigh phenotype could be prevented by modulating YAP signal-
ling.
Drugs targeting the phenotypic switch will require thorough and
elaborate clinical testing before more personalised and eﬃcient treat-
ments can be oﬀered to melanoma patients. Nevertheless, before such
drugs come into clinical practice, other kinase inhibitors that are cur-
rently in clinical use in diﬀerent cancers will be further tested and
might induce more durable treatment outcomes in patients with ad-
vanced stage melanoma when combined with current targeted thera-
pies.
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